While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more
CM Life Sciences, a blank check company formed by Casdin Capital and Corvex Management targeting a life science business, raised $385 million by offering 38.5 million units at $10. The company offered 3.5 million more units than anticipated. Each unit...read more
Four IPOs and six SPACs entered the public markets this past week led by CureVac (CVAC), which posted the largest first-day pop for a US IPO since 2005. German biotech CureVac (CVAC) raised $213 million at a $2.8 billion market cap and...read more
CM Life Sciences, a blank check company formed by Casdin Capital and Corvex Management targeting a life science business, filed on Friday with the SEC to raise up to $350 million in an initial public offering. The New York, NY-based company plans to raise...read more
US IPO Weekly Recap: The September IPO market kicks off with a quiet week
While there were no IPOs this past week, five SPACs went public ahead of the post-Labor Day rush. Casdin Capital and Corvex Management’s SPAC CM Life Sciences (CMLFU) upsized to raise $385 million. Led by the firms’ founders,...read more
Casdin Capital and Corvex Management's SPAC CM Life Sciences prices upsized $385 million IPO at $10
CM Life Sciences, a blank check company formed by Casdin Capital and Corvex Management targeting a life science business, raised $385 million by offering 38.5 million units at $10. The company offered 3.5 million more units than anticipated. Each unit...read more
US IPO Weekly Recap: Coronavirus vaccine developer CureVac pops 249% in a 4 IPO week
Four IPOs and six SPACs entered the public markets this past week led by CureVac (CVAC), which posted the largest first-day pop for a US IPO since 2005. German biotech CureVac (CVAC) raised $213 million at a $2.8 billion market cap and...read more
Casdin Capital and Corvex Management's SPAC CM Life Sciences files for a $350 million IPO
CM Life Sciences, a blank check company formed by Casdin Capital and Corvex Management targeting a life science business, filed on Friday with the SEC to raise up to $350 million in an initial public offering. The New York, NY-based company plans to raise...read more